Cargando…
Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a very aggressive form of cancer with a poor diagnosis and prognosis. The first line treatment for MPM is a combination of cisplatin and Pemetrexed, which displayed limited efficacy and severe side effects. The naturally occurring compound phenethyl isothiocya...
Autores principales: | Denis, Iza, Cellerin, Laurent, Gregoire, Marc, Blanquart, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294387/ https://www.ncbi.nlm.nih.gov/pubmed/25361002 |
Ejemplares similares
-
Irreversible Inhibition of Glutathione S-Transferase by Phenethyl Isothiocyanate (PEITC), a Dietary Cancer Chemopreventive Phytochemical
por: Kumari, Vandana, et al.
Publicado: (2016) -
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma
por: Blondy, Thibaut, et al.
Publicado: (2020) -
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
por: Bensaid, Douae, et al.
Publicado: (2018) -
Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy
por: Porta, Chiara, et al.
Publicado: (2023) -
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis
por: Smeele, Patrick, et al.
Publicado: (2018)